Table 1.
Concentration (µmol/g) of brain metabolites in STZ-treated (5 mg/kg) mice.
| Brain regions | Treatment groups | Glu | GABA | Gln | Asp | NAA | m-Ino | Tau | Cho | p-Cho | GPC | Cre |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cerebral cortex | Control | 12.4 ± 0.6 | 2.3 ± 0.2 | 4.5 ± 0.3 | 2.8 ± 0.2 | 6.5 ± 0.4 | 6.3 ± 0.4 | 10.2 ± 1.4 | 0.04 ± 0.01 | 0.78 ± 0.06 | 1.4 ± 0.1 | 13.0 ± 1.2 |
| ICV-STZ | 11.6 ± 0.8** | 2.2 ± 0.1* | 4.5 ± 0.3 | 2.7 ± 0.3 | 6.0 ± 0.4** | 6.7 ± 0.6* | 9.5 ± 1.0 | 0.05 ± 0.01 | 0.77 ± 0.07 | 1.3 ± 0.1 | 12.1 ± 0.9* | |
| Hippo-campus | Control | 11.6 ± 0.7 | 3.0 ± 0.4 | 4.6 ± 0.3 | 2.5 ± 0.2 | 6.6 ± 0.5 | 6.9 ± 0.6 | 8.6 ± 1.2 | 0.05 ± 0.01 | 0.78 ± 0.06 | 1.3 ± 0.1 | 13.5 ± 0.9 |
| ICV-STZ | 10.8 ± 0.6** | 2.7 ± 0.1* | 4.6 ± 0.3 | 2.4 ± 0.2 | 6.0 ± 0.3** | 7.4 ± 0.5* | 7.8 ± 0.6* | 0.04 ± 0.01 | 0.75 ± 0.04 | 1.3 ± 0.1 | 12.7 ± 0.5** |
The concentrations of metabolites were measured in the cortical and hippocampal tissue extracts from unedited 1H-[13C]-NMR spectrum using [2-13C]glycine as reference. Values are presented as mean±SD. *p < 0.05 and **p < 0.01 when ICV-STZ-treated mice were compared with controls.
Asp: aspartate; Cho: Choline; p-Cho: phosphocholine; GPC: glycerophosphocholine; Cre: creatine; GABA: γ-aminobutyric acid; Glu: glutamate; Gln: glutamine; ICV-STZ: intracerebroventricular-streptozotocin: m-Ino: myo-inositol; NAA: N-acetyl aspartate; Tau: Taurine.